Our Pipeline
Strategic target selection for pyrrolobenzodiazepine (PBD)-based antibody drug conjugates (ADCs) and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematologic and solid tumor cancers with significant unmet need.
ADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.
The agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.
*We believe that our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL, our Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL and our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that subsequent Phase 3 clinical trials will be confirmatory clinical trials.
LEAD CANDIDATE
Loncastuximab Tesirine (Lonca)
Lonca is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and conjugated through a linker to a PBD-dimer toxin. Once bound to a CD19-expressing cell, Lonca is internalized into the cell where enzymes release the PBD-based warhead.
CD19 is an ideal target for an ADC approach
CD19 is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia, while its expression in healthy tissue is restricted.
Lonca is the focus of the LOTIS Clinical Development Program
In clinical trials, lead candidate Lonca has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell, mantle cell, and follicular lymphomas.
The clinical development of this product is ongoing. Loncastuximab Tesirine (ADCT-402) is an investigational agent. Safety and efficacy has not yet been established.
2nd LEAD CANDIDATE
Camidanlumab Tesirine (Cami)
Cami is ADCT’s second lead candidate. It has demonstrated significant clinical activity in heavily pretreated patients with Hodgkin lymphoma. Based on its mechanism targeting CD25/regulatory T cells, Cami is also demonstrating potential in the treatment of solid tumors.
Cami targets CD25/regulatory T cells
Cami is an ADC composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to a PBD dimer toxin. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, Cami depletes CD25-positive Tregs in the local tumor environment, which enhances immune-mediated anti-tumor activity.
Cami is being evaluated in several clinical trials
Studies include a pivotal phase 2 clinical trial in patients with relapsed or refractory (R/R) Hodgkin lymphoma (NCT04052997); a phase 1a/1b clinical trial in patients with R/R Hodgkin lymphoma and non-Hodgkin lymphoma (NCT02432235); and a phase 1b clinical trial in solid tumors (NCT03621982).
The clinical development of this product is ongoing. Camidanlumab Tesirine (ADCT-301) is an investigational agent. The safety and efficacy has not yet been established.
ADCT-602 Targeting CD22
ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD dimer toxin. Once bound to a CD22-expressing cell, ADCT-602 is internalized into the cell where enzymes release the PBD-based warhead. CD22 is an attractive and clinically validated ADC target. CD22 is highly expressed on most malignant B-cells, including expression in more than 90% of patients with B-cell acute lymphoblastic leukemia (ALL).
ADCT-602 is being evaluated in a phase I/II clinical trial in patients with relapsed or refractory B-cell ALL (NCT03698552). The trial is being led by The University of Texas MD Anderson Cancer Center.
ADCT-601 Targeting AXL
ADCT-601 is an ADC composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using Glycoconnect™ technology (licensed from Synaffix BV) to a linker with a PBD-dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell, where enzymes release the PBD-based warhead. AXL is an ideal target for an ADC approach, as it is highly overexpressed in many solid tumors (eg, lung, breast, prostate, pancreas, glioma, and esophageal) and hematological malignancies (eg, acute and chronic myeloid leukemia).
ADCT-601 is being evaluated in a phase 1 clinical trial in patients with selected advanced solid tumors (NCT03700294).
ADCT-901 Targeting KAAG1
ADCT-901 is an ADC composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD-dimer cytotoxin. KAAG1 is an attractive novel tumor target for ADC development as (i) it is an intracellular target by definition, but becomes exposed on the membrane of tumor cells, (ii) it has high expression in tumors with high unmet medical need, including ovarian cancer and triple negative breast cancer, while its expression on healthy tissue is very restricted, and (iii) it internalizes and co-localizes with lysosomal-associated membrane protein 1, a lysosomal marker, which shows that the target is efficiently transported to the cellular compartment where efficient release of the cytotoxin is expected.
ADCT-901 is being developed for the treatment of advanced solid tumors with high unmet medical needs, including platinum resistant ovarian cancer and triple negative breast cancer.
ADCT-701 Targeting DLK-1
ADCT-701 is an ADC composed of a humanized monoclonal antibody (HuBa-1-3D) directed against human DLK-1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD-dimer cytotoxin. DLK-1 is widely expressed during fetal development; however, its expression is highly restricted in adults. DLK-1 is an attractive novel tumor target for ADC development as it is expressed in adults in several tumors, such as neuroblastoma, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and acute myeloid leukemia (AML).
ADCT-701 is being developed for the treatment of advanced solid tumors with high unmet medical needs, neuroblastoma, HCC, and SCLC.
